mbadoc
Posted - 08/21/24
$XOMA
epsguid
Posted - 1 month ago
$XOMA reported a loss of $0.28, consensus was ($0.26) via @eWhispers #epsmiss http://eps.sh/d/xoma
liverboystreet
Posted - 1 month ago
$XOMA fu xoma
NVDAMillionaire
Posted - 1 month ago
$XOMA XOMA (NASDAQ:XOMA) Poised for Continued Growth as Royalty Aggregator Model Gains Traction http://beyondspx.com/2024/08/02/xoma-nasdaqxoma-poised-for-continued-growth-as-royalty-aggregator-model-gains-traction/
WaynD01
Posted - 2 months ago
$ZVRA @Mattedbumhair Here is your answer from William Blair on Arimo CRL and how Zevra addressed it. Some for $ARDX board also asked the same question. FYI, $XOMA
WaynD01
Posted - 2 months ago
$XOMA Some analysts' highlights
WaynD01
Posted - 2 months ago
$XOMA If you have ever wondered about your partner $ZVRA : Upcoming FDA Advisory Committee meeting on Aug 02 and PDUFA Sept 21, 2024. Arimoclomol NDA is for a rare disease drug with no approved drug in US and is strongly supported by patients and NPC community with Testimonials and FDA Advocacy ( https://nnpdf.org/wp-content/uploads/2024/02/NNPDF-Community-Response-FDA-Arimoclomol-Review-FINAL.pdf ). Also, the recent guidelines and legalization on rare diseases provide a very good odds for the approval. Now a great entry point brought by the macro socio/economic weaknesses.
WaynD01
Posted - 2 months ago
$ZVRA $XOMA Will these analysts continue reiterate the PT in the evening of Aug 02 after positive Adcom vote and later on Approval? Or will they do something else. You figure it out and decide what to do..
WaynD01
Posted - 2 months ago
$ZVRA $XOMA "He who has ears to hear, let him hear"
erevnon
Posted - 2 months ago
HC Wainwright & Co. reiterates XOMA $XOMA at Buy and maintains a price target of https://marketsblock.com/stock-upgrades-and-downgrades/
liverboystreet
Posted - 06/26/24
$XOMA fu xoma
Stocksrunner
Posted - 06/21/24
$XOMA Despite an 11.5% loss over the past month, the recent surge indicates strong buying interest. Can this momentum continue? https://stocksrunner.com/symbol/XOMA
Thestocktraderhubzee
Posted - 3 months ago
$XOMA Laser Photonics Announces The Launch Of Its Sabertech Laser Cutting Systems, Joining Its Product Lines For Laser Cleaning, Welding, Marking And Engraving Systems
DonCorleone77
Posted - 3 months ago
$XOMA $VIRX $DAWN Xoma receives $8.1M milestone related to Day One's sale of PRV XOMA Corporation (XOMA) announced it has received an $8.1M milestone payment from Viracta Therapeutics (VIRX), related to Day One Biopharmaceuticals' (DAWN) recent sale of its Priority Review Voucher, PRV, for $108 million to an undisclosed buyer. "OJEMDA offers patients six months of age and older who have relapsed or refractory BRAF-altered pediatric low-grade glioma the only approved therapy studied in and approved specifically for pLGG driven by BRAF fusions," stated Owen Hughes, Chief Executive Officer of XOMA. "With this milestone in hand, we have more than recouped our initial capital outlay. And importantly, we anticipate future royalties on OJEMDA will contribute to a growing portfolio of royalty receipts that will help us drive sustainable free cash flow generation over time."
Drtymax
Posted - 3 months ago
$LADXD $CYTR far better deal with $XOMA on Aldox
DonCorleone77
Posted - 3 months ago
$XOMA LadRx, ImmunityBio mutually agree to terminate Aldoxorubicin license The company states: "LadRx is pleased to announce that the Company and NantCell, Inc., together with NantCell's parent company ImmunityBio, Inc., have agreed to a mutual termination of the license of aldoxorubicin entered into in 2017. With the termination of the license agreement between LadRx and NantCell, LadRx regains control of aldoxorubicin. In 2023, LadRx transferred the royalty and milestone rights of arimoclomol and aldoxorubicin to XOMA Corporation (XOMA) in exchange for $5 million in upfront gross proceeds, up to an additional $2 million for milestones related to arimoclomol and $5 million for milestones related to aldoxorubicin. XOMA consented to the mutual termination of the LadRx-NantCell agreement in order to facilitate the return of the program to LadRx. In parallel, LadRx and XOMA have amended their 2023 Royalty Purchase Agreement to provide XOMA with a low-single-digit synthetic royalty on aldoxorubicin and a mid-single-digit percentage of any economics derived by LadRx from future out-license agreements related to aldoxorubicin. The agreement between LadRx and XOMA regarding future royalties and milestones associated with arimoclomol is not affected by the termination of the aldoxorubicin license between LadRx and NantCell."
TheBioFreak
Posted - 05/31/24
$XOMA Good News
NJgolfer
Posted - 05/22/24
$XOMA looks ready to breakout. Hardly followed up as a biotech royalty play, these guys are top notch. A very capital efficient business model with lots of opportunities.
IN0V8
Posted - 4 months ago
$XOMA Leerink Partners raises target price to $42 from $40
Zellchair
Posted - 4 months ago
$FBIO One year graph with FBIO in blue vs peers I've written about here before (see previous posts about comparison in sales and market cap). Writing it again, never seen such a mispriced/cheap stock. 8 commercial and 25 clinical products, which together are valued at less than $1 M each, when sales were $84.5 M in 2023 and there are completed deals worth about $900 M. It is extremely difficult today, for me, to see how DFD-29, Cosibelimab, Dotinurad and CUTX -101, all of which have presented their efficacy and safety from Phase 3 (Dotinated Japan, see previous post), should fail not to sell for over $1 B each in total sales (some for significantly more). FBIO market cap today? $32 M. $XOMA $LGND $RPRX
Zellchair
Posted - 4 months ago
$FBIO $XOMA Reports Q1 revenue $1.5M and the stock is trading up 5% ($296 M market cap)... $LGND +17% last week... When will the market find and understand $FBIO? $XBI $IBB
Stocksrunner
Posted - 4 months ago
$XOMA XOMA misses estimates with GAAP EPS of -$0.86. Revenue of $1.49M also disappoints. Reassess positions based on fundamentals. https://stocksrunner.com/symbol/XOMA
epsguid
Posted - 4 months ago
$XOMA reported a loss of $0.86, consensus was ($0.71) via @eWhispers #epsmiss http://eps.sh/d/xoma
DonCorleone77
Posted - 4 months ago
$XOMA Xoma reports Q1 EPS (86c), consensus (81c) Reports Q1 revenue $1.5M, consensus $1.33M. "We continue to build the foundation for accelerating value creation with a disciplined approach to capital deployment," stated Owen Hughes, Chief Executive Officer of XOMA. "In recent months, we've completed the acquisition of Kinnate, acquired economic interests in two commercial assets, as well as in two first-in-class Phase 3 assets, and initiated our first share buyback program on the heels of securing the VABYSMO royalty-backed loan with Blue Owl. Lastly, and most importantly, the FDA approved OJEMBA, Day One Biopharmaceuticals' type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement or BRAF V600 mutation, ushering in an important new treatment for children living with relapsed or refractory pLGG."
Zellchair
Posted - 4 months ago
$FBIO Why is Fortress Biotech significantly undervalued? (Part 200 or something) $XBI $XOMA is another royalty peer that is probably most similar to Fortress as they invest in an earlier event. Total Revenues 2023 Ligand Pharmaceuticals $LGND: $131,3 M Fortres Biotech: $84,5 M Xoma: $4,8 M Market Cap Today: Ligand Pharmaceuticals: $1328 M Xoma: $289 M Fortres Biotech: $33 M And then Fortress is also a co-owner in all of its 11 companies (majority owner in several, see previous posts).
BiotechJedi1728
Posted - 4 months ago
$DARE $XOMA
BiotechJedi1728
Posted - 04/30/24
$XOMA
Starts at 5:30. Break all rules Also, Xoma flat out will do a buyout of some of its partners and/or buy their stock. Xoma bought $9.5M shares of KNTE before eventually buying them out this year. https://www.google.com/search?q=xoma+buyout&ie=UTF-8&oe=UTF-8&hl=en-us&client=safari#fpstate=ive&ip=1&vld=cid:d50c6aca,vid:G4ZuoUt5SQI,st:0
BiotechJedi1728
Posted - 04/30/24
$DARE When your partner tells you, oh yea. Just go get some funding at $XOMA that’s what we $BAYRY did to finish off a trial. Really not a big deal when you are going to have $100M+ quarters in sales in two years.
Gagull
Posted - 04/30/24
$DARE $XOMA $22M Thats some kind of winding terms. Love cash in hand and that behind the scenes, other people see value in the pipe.